| Literature DB >> 32450800 |
Giedre Gefenaite1, Jonas Björk2,3, Susanne Iwarsson4, Björn Slaug4, Steven M Schmidt4, Maria H Nilsson4,5,6.
Abstract
BACKGROUND: External housing-related control beliefs (HCB) and general self-efficacy (GSE) influence different health outcomes in the general ageing population, but there is no information of their role in people ageing with Parkinson's disease (PD). This study aimed to longitudinally assess the role of external HCB and GSE on the association between housing accessibility and activities of daily living (ADL) among people ageing with PD.Entities:
Keywords: ADL; General self-efficacy; Housing accessibility; Housing-related control beliefs
Year: 2020 PMID: 32450800 PMCID: PMC7249684 DOI: 10.1186/s12877-020-01574-z
Source DB: PubMed Journal: BMC Geriatr ISSN: 1471-2318 Impact factor: 3.921
Descriptive characteristics according to the categorized RAPS (N = 130)
| Total | Fewer barriers than expected | Expected barriers | More barriers than expected | ||
|---|---|---|---|---|---|
| n = 130 (100%) | |||||
| Sex (male), T1 | 84 (64.6) | 27 (71.1) | 43 (68.3) | 14 (48.3) | 0.11 |
| Civil status (married/cohabiting), T1 | 85 (65.4) | 27 (71.1) | 44 (69.8) | 14 (48.3) | 0.09 |
| Education (university/college), T1 | 47 (36.2) | 18 (47.4) | 23 (36.5) | 6 (20.7) | 0.08 |
| Lived in Sweden for most of the time, T1 | 127 (97.7) | 36 (94.7) | 62 (98.4) | 29 (100) | 0.32 |
| Own their home, T1 | 99 (76.2) | 31 (81.6) | 49 (77.8) | 19 (65.5) | 0.28 |
| Moved since T1, T2 | 20 (15.4) | 5 (13.2) | 10 (15.9) | 5 (17.2) | 0.89 |
| Housing adjustments since T1, T2 | 26 (20.6) | 12 (32.4) | 7 (11.1) | 7 (26.9) | 0.03 |
| Age, T1 | 68.3 (8.6) | 70.1 (9.1) | 66 (7.8) | 71 (8.6) | 0.01 |
| External HCB, T1 | 38.8 (10.6) | 39.4 (9.2) | 36 (8.8) | 44.2 (13.6) | 0.003 |
| GSE, T1 | 29.6 (6.1) | 29.4 (5.8) | 30.1 (6.4) | 28.9 (6.1) | 0.67 |
| Satisfied with income, T1 | 7 (5–9) | 7.5 (5.8–10) | 7 (5–9) | 7.5 (5–8) | 0.97 |
| PD duration, T1 | 8 (5–13) | 8 (5–11.5) | 7 (4–12.3) | 10 (6.3–14.8) | 0.64 |
| PD severity, HY: off condition, T1 | 3 (2–4) | 2 (1.8–4) | 2 (2–3) | 3.5 (3–4) | 0.03 |
| Depressive symptoms, T1 | 5 (5–7) | 6 (5–7) | 5 (5–6) | 6 (5–7) | 0.07 |
Note. RAPS relative accessibility problem score; HCB housing-related control beliefs; GSE general self-efficacy; PD Parkinson’s disease; HY Hoehn and Yahr scale; ANOVA one-way analysis of variance
Correlations between the exposure, outcomes and potential moderators (N = 130)
| RAPS, T1 | Functional limitations, T1 | External HCB, T1 | GSE, T1 | Generic ADL, T2 | ADL specific to PD, T2 | |
|---|---|---|---|---|---|---|
| RAPS, T1 | 1.00 | 0.09 | 0.15 | −0.06 | 0.10 | 0.2* |
| Functional limitations, T1 | 1.00 | 0.42** | −0.24** | 0.58** | 0.54** | |
| External HCB, T1 | 1.00 | −0.22* | 0.21* | 0.19* | ||
| GSE, T1 | 1.00 | −0.24** | −0.25** | |||
| Generic ADL, T2 | 1.00 | 0.67** | ||||
| ADL specific to PD, T2 | 1.00 |
Note. RAPS relative accessibility problem score; HCB housing-related control beliefs; GSE general self-efficacy; ADL activities of daily living; PD Parkinson’s Disease. Pearson correlation coefficients are presented between continuous variables (RAPS, functional limitations, external HCB and GSE), while correlations with categorical generic ADL and ADL specific to PD are Spearman correlation coefficients
* p-value ≤0.05 level (2-tailed); ** p-value ≤0.01 level (2-tailed)
The effect of RAPS on generic ADL (Models A1–3 N = 128; Models B1–3 N = 130)
| Model A1 | Model A2 | Model A3 | Model B1 | Model B2 | Model B3 | |
|---|---|---|---|---|---|---|
| OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) | |
| RAPS, T1 | 1.02 (0.96–1.09) | 1.02 (0.96–1.09) | 1.32 (0.96–1.81) | 1.02 (0.96–1.09) | 1.03 (0.97–1.09) | 1.76 (1.09–2.81)* |
| Functional limitations, T1 | 2.4 (1.75–3.28)*** | 2.29 (1.66–3.15)*** | 2.31 (1.68–3.2)*** | 2.41 (1.76–3.3)*** | 2.5 (1.77–3.53)*** | 2.9 (1.9–4.41)*** |
| External HCB, T1 | 1.04 (0.99–1.09) | 1.05 (0.99–1.11) | ||||
| RAPS*External HCB | 0.99 (0.99–1.00) | |||||
| GSE, T1 | 0.89 (0.81–0.98)* | 0.88 (0.8–0.97)** | ||||
| RAPS*GSE | 0.98 (0.97–1.00)* | |||||
| R square | 0.35 | 0.36 | 0.37 | 0.35 | 0.38 | 0.41 |
Note. RAPS relative accessibility problem score; ADL activities of daily living; HCB housing-related control beliefs; GSE general self-efficacy; OR odds ratio; CI confidence interval
* p-value ≤0.05 level (2-tailed); ** p-value ≤0.01 level (2-tailed); *** p-value ≤0.001 level (2-tailed)
The effect of RAPS on ADL specific to PD (Models A1–3 N = 128; Models B1–3 N = 130)
| Model A1 | Model A2 | Model A3 | Model B1 | Model B2 | Model B3 | |
|---|---|---|---|---|---|---|
| OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) | |
| RAPS, T1 | 1.07 (1.00–1.13)* | 1.06 (1.00–1.13)* | 1.50 (1.09–2.06)* | 1.06 (1.00–1.13)* | 1.07 (1.00–1.13)* | 1.29 (0.9–1.84) |
| Functional limitations, T1 | 2.03 (1.56–2.65)*** | 1.91 (1.46–2.50)*** | 1.98 (1.49–2.63)*** | 2.05 (1.58–2.67)*** | 2.08 (1.57–2.75)*** | 2.14 (1.59–2.88)*** |
| External HCB, T1 | 1.05 (1.00–1.10)* | 1.35 (1.06–1.71)** | ||||
| RAPS*External HCB | 0.99 (0.99–1.00)* | |||||
| GSE, T1 | 0.89 (0.81–0.96)** | 1.09 (0.74–1.6) | ||||
| RAPS*GSE | 0.99 (0.98–1.01) | |||||
| R square | 0.32 | 0.34 | 0.37 | 0.32 | 0.36 | 0.37 |
Note.RAPS relative accessibility problem score; ADL activities of daily living; PD Parkinson’s Disease; HCB housing-related control beliefs; GSE general self-efficacy; OR odds ratio; CI confidence interval
* p-value ≤0.05 level (2-tailed); ** p-value ≤0.01 level (2-tailed); *** p-value ≤0.001 level (2-tailed)